Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson
Queensland Health
US Army
Fish and Richardson
Argus Health

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,866,591

« Back to Dashboard

Which drugs does patent 5,866,591 protect, and when does it expire?

Patent 5,866,591 protects ULTIVA and is included in one NDA. There has been one Paragraph IV challenge on Ultiva.

Protection for ULTIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,866,591

Title: Stable formulations of remifentanil
Abstract:Stable formulations of 3-[4-methoxycarbonyl-4-[(1 -oxopropyl)phenylamino]-1-piperidine]propanoic acid, methyl ester, generally referred to as remifentanil, are disclosed. In particular, stabilized lyophilized solid composition are disclosed comprising certain acids, most preferably comprising glycine.
Inventor(s): Gatlin; Larry Alan (Chapel Hill, NC), Heiman; Shirley Ann (Cary, NC), Lewis; Janet Sue (Cary, NC)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/926,930
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mylan Institutional
remifentanil hydrochloride
INJECTABLE;INJECTION020630-001Jul 12, 1996RXYesNo► Subscribe► SubscribeY
Mylan Institutional
remifentanil hydrochloride
INJECTABLE;INJECTION020630-002Jul 12, 1996RXYesNo► Subscribe► SubscribeY
Mylan Institutional
remifentanil hydrochloride
INJECTABLE;INJECTION020630-003Jul 12, 1996RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Argus Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus